title: [Calcitonin nasal spray for Paget's disease of the bone].
abstract: 3 patients with prolonged, diffuse, bone pain due to Paget's disease were treated with intranasal salmon calcitonin, 200-400 U/d for 12 months. Within the first 3 months, in all 3 bone turnover decreased 31-35% (as assessed by serum alkaline phosphatase activity and urinary hydroxyproline/creatinine ratio). After 1 year of nasal calcitonin the reduction in serum alkaline phosphatase was 24%, and in urinary hydroxyproline 10%. In addition, pain and functional impairment markedly improved during the year. It is concluded that daily nasal calcitonin spray is well tolerated and effective initial treatment for Paget's disease of the bone.
authors.affiliation: Endocrinology Institute, Central Hospital of the Emek, Afula.
authors.forename: R
authors.initials: R
authors.lastname: Luboshitzky
authors.forename: R
authors.initials: R
authors.lastname: Bar-Shalom
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000336:Aerosols; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000700:Analgesics / Q000008:administration & dosage* / Q000627:therapeutic use; D002116:Calcitonin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
chemical_list: D000336:Aerosols; D000700:Analgesics; C028815:salmon calcitonin; D002116:Calcitonin; D000469:Alkaline Phosphatase; D006909:Hydroxyproline